CJC-1295 with DAC vs Finasteride
Well Studied vs FDA Approved
monitor Mechanism-based · 51% Both CJC-1295 with DAC and Finasteride can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed.
Molecular Data
CJC-1295 with DAC Finasteride
Weight 3,647.28 Da 372.54 Da
Half-life 6-8 days 6-8 hours (DHT suppression persists ~24 hours)
Chain 30 amino acids —
Type GHRH analog with DAC Synthetic 4-azasteroid compound
Key Benefits
CJC-1295 with DAC
01 Convenient weekly dosing
02 Sustained GH/IGF-1 elevation
03 6-8 day half-life
04 Significant body composition changes
Finasteride
01 Reduces scalp DHT by approximately 66% at 1mg daily
02 Slows or stops hair loss progression in roughly 90% of men
03 Produces visible hair regrowth in approximately 48% of men within 1-2 years
04 FDA-approved with over 25 years of clinical use and long-term safety data
05 Convenient once-daily oral dosing with no injections required
06 Well-characterized side effect profile with low incidence of adverse events
07 Can be combined with minoxidil for enhanced efficacy
Dosing Protocols
CJC-1295 with DAC
1-2mg weekly / Once or twice weekly (e.g., Monday/Thursday for split dosing)
Conservative Anti-Aging 1mg Once weekly
Standard Protocol 2mg Once weekly
Split Dosing 1mg Twice weekly (Mon/Thu)
Loading Protocol 2mg first week, then 1mg Weekly
Finasteride
1mg/day (hair loss) or 5mg/day (BPH) / Once daily
Side Effects
CJC-1295 with DAC
Water retention
Joint pain
Carpal tunnel symptoms
Finasteride
Decreased libido (reported in 1.8% of men in clinical trials vs 1.3% placebo)
Erectile dysfunction (reported in 1.3% vs 0.7% placebo)
Decreased ejaculate volume (reported in 0.8% vs 0.4% placebo)
Contraindications
Diabetes history
Cancer history
Predisposed sleep apnea
Women who are pregnant or may become pregnant (finasteride is teratogenic and can cause abnormalities of external genitalia in a male fetus; even handling crushed tablets poses a risk)
Women who are breastfeeding
Known hypersensitivity to finasteride or any component of the formulation
Severe hepatic impairment (finasteride is metabolized by the liver)
Pediatric patients (not indicated for use in children)
Research Evidence
CJC-1295 with DAC Finasteride
Status Well Studied FDA Approved
References 4 studies 5 studies
Latest 2025 —
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.